definiens: means, subject to Section 4.11, with respect to any Collaboration Compound, Candidate Drug or Product, any compound or product that has the 3same Framework as such Collaboration Compound, Candidate Drug or Product and, if such Collaboration Compound, Candidate Drug or Product is:(a ) an Alpha4Beta2 Agonist, ( i ) has an [ * * * * * * * * ] at least equal to [ * * * * * * * * ], ( ii ) has [ * * * * * * * * ] and ( iii ) hasactivity in [ * * * * * * * * ] at a dose of less than or equal to [ * * * * * * * * ] or activity in a Replacement Assay at theapplicable dose if and as agreed pursuant to Section 4.11.3 or, if applicable, determined by an Expert pursuant toSection 14.3 ( accelerated arbitration);(b ) a Selective Alpha7 Compound, ( i ) has [ * * * * * * * * ] at least equal to [ * * * * * * * * ], ( ii ) has [ * * * * * * * * ] and ( iii ) hasactivity in [ * * * * * * * * ] or activity in a Replacement Assay at the applicable dose if and as agreed pursuant toSection 4.11.3 or, if applicable, determined by an Expert pursuant to Section 14.3 ( accelerated arbitration);(c ) a Dual Pharmacology Compound, ( i ) has an [ * * * * * * * * ] at least equal to [ * * * * * * * * ], ( ii ) has [ * * * * * * * * ] and(iii ) has activity in either ( A ) [ * * * * * * * * ], or ( B ) [ * * * * * * * * ] or, in either case ( ( A ) or ( B ) ), activity in a ReplacementAssay at the applicable dose if and as agreed pursuant to Section 4.11.3 or, if applicable, determined by anExpert pursuant to Section 14.3 ( accelerated arbitration ) ; or(d ) an Other NNR Compound, ( i ) has an [ * * * * * * * * ] at least equal to [ * * * * * * * * ], ( ii ) has [ * * * * * * * * ] based on afunctional assay designated and approved by the Parties, subject to referral of any disputes to an Expertpursuant to Section 14.3, in accordance with Section 4.11.2 for the applicable NNR ( or, if there is no suchfunctional assay designated and approved by the Parties ( or by an Expert pursuant to Section 14.3 ) for theapplicable NNR, such Other NNR Compound has a [ * * * * * * * * ], [ * * * * * * * * ] ; provided that this clause ( ii ) shall notapply to ( A ) a Collaboration Candidate that does not meet Minimum Binding Affinity or a Licensed Derivative ofany Collaboration Compound, Candidate Drug ( other than an Option Compound Candidate Drug ) or Product ( otherthan an Option Compound Product ) that is not itself an Alpha4Beta2 Agonist or ( B ) an Option CompoundCandidate Drug that is not a [ * * * * * * * * ] but that is a Licensed Derivative of an Option Compound Candidate Drugthat is a [ * * * * * * * * ] ; and ( iii ) has activity in an [ * * * * * * * * ] assay ( such assay, and the criteria for activity in suchassay, to be designated and approved by the Parties, subject to referral of any disputes to 4an Expert pursuant to Section 14.3 ( accelerated arbitration ), in accordance with Section 4.11.2 ) for the applicableNNR at a dose of less than or equal to [ * * * * * * * * ] or has activity in a Replacement Assay at the applicable dose ifand as agreed pursuant to Section 4.11.3 or, if applicable, determined by an Expert pursuant to Section 14.3(accelerated arbitration ) . For purposes of this Section 1.9(d ), the applicable NNR for : ( A ) a CollaborationCandidate that does not meet Minimum Binding Affinity or a Licensed Derivative of any Collaboration Compound, Candidate Drug ( other than an Option Compound Candidate Drug ) or Product ( other than an Option CompoundProduct ) that is not itself an Alpha4Beta2 Agonist shall be the Alpha4Beta2 NNR and the [ * * * * * * * * ] assay shall beas provided in clause ( iii ) of Section 1.9(a ) ; ( B ) an Option Compound Candidate Drug that is a Licensed Derivativeof an Option Compound Candidate Drug that is a [ * * * * * * * * ] shall be the [ * * * * * * * * ] and the [ * * * * * * * * ] assay shall beas provided in clause ( iii ) of Section 1.9(b ) ; ( C ) an Option Compound Candidate Drug that is a Licensed Derivativeof an Option Compound Candidate Drug that is a [ * * * * * * * * ] shall be the [ * * * * * * * * ] and the [ * * * * * * * * ] assay shall beas provided in clause ( iii ) of Section 1.9(c ) ; and ( D ) an Option Compound Candidate Drug that is an Other NNRCompound or a Licensed Derivative of an Other NNR Compound shall be the applicable NNR